These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 34555614)

  • 1. Pharmacological inhibition of KDM5A for cancer treatment.
    Yang GJ; Wu J; Miao L; Zhu MH; Zhou QJ; Lu XJ; Lu JF; Leung CH; Ma DL; Chen J
    Eur J Med Chem; 2021 Dec; 226():113855. PubMed ID: 34555614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The emerging role of KDM5A in human cancer.
    Yang GJ; Zhu MH; Lu XJ; Liu YJ; Lu JF; Leung CH; Ma DL; Chen J
    J Hematol Oncol; 2021 Feb; 14(1):30. PubMed ID: 33596982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screen-identified selective inhibitor of lysine demethylase 5A blocks cancer cell growth and drug resistance.
    Gale M; Sayegh J; Cao J; Norcia M; Gareiss P; Hoyer D; Merkel JS; Yan Q
    Oncotarget; 2016 Jun; 7(26):39931-39944. PubMed ID: 27224921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological Inhibition of LSD1 for Cancer Treatment.
    Yang GJ; Lei PM; Wong SY; Ma DL; Leung CH
    Molecules; 2018 Dec; 23(12):. PubMed ID: 30518104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The KDM5 family of histone demethylases as targets in oncology drug discovery.
    Rasmussen PB; Staller P
    Epigenomics; 2014 Jun; 6(3):277-86. PubMed ID: 25111482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective Inhibition of Lysine-Specific Demethylase 5A (KDM5A) Using a Rhodium(III) Complex for Triple-Negative Breast Cancer Therapy.
    Yang GJ; Wang W; Mok SWF; Wu C; Law BYK; Miao XM; Wu KJ; Zhong HJ; Wong CY; Wong VKW; Ma DL; Leung CH
    Angew Chem Int Ed Engl; 2018 Oct; 57(40):13091-13095. PubMed ID: 29968419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-based design and discovery of potent and selective KDM5 inhibitors.
    Nie Z; Shi L; Lai C; O'Connell SM; Xu J; Stansfield RK; Hosfield DJ; Veal JM; Stafford JA
    Bioorg Med Chem Lett; 2018 May; 28(9):1490-1494. PubMed ID: 29627262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells.
    Vinogradova M; Gehling VS; Gustafson A; Arora S; Tindell CA; Wilson C; Williamson KE; Guler GD; Gangurde P; Manieri W; Busby J; Flynn EM; Lan F; Kim HJ; Odate S; Cochran AG; Liu Y; Wongchenko M; Yang Y; Cheung TK; Maile TM; Lau T; Costa M; Hegde GV; Jackson E; Pitti R; Arnott D; Bailey C; Bellon S; Cummings RT; Albrecht BK; Harmange JC; Kiefer JR; Trojer P; Classon M
    Nat Chem Biol; 2016 Jul; 12(7):531-8. PubMed ID: 27214401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-Based Engineering of Irreversible Inhibitors against Histone Lysine Demethylase KDM5A.
    Horton JR; Woodcock CB; Chen Q; Liu X; Zhang X; Shanks J; Rai G; Mott BT; Jansen DJ; Kales SC; Henderson MJ; Cyr M; Pohida K; Hu X; Shah P; Xu X; Jadhav A; Maloney DJ; Hall MD; Simeonov A; Fu H; Vertino PM; Cheng X
    J Med Chem; 2018 Dec; 61(23):10588-10601. PubMed ID: 30392349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural Basis for KDM5A Histone Lysine Demethylase Inhibition by Diverse Compounds.
    Horton JR; Liu X; Gale M; Wu L; Shanks JR; Zhang X; Webber PJ; Bell JSK; Kales SC; Mott BT; Rai G; Jansen DJ; Henderson MJ; Urban DJ; Hall MD; Simeonov A; Maloney DJ; Johns MA; Fu H; Jadhav A; Vertino PM; Yan Q; Cheng X
    Cell Chem Biol; 2016 Jul; 23(7):769-781. PubMed ID: 27427228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended Recognition of the Histone H3 Tail by Histone Demethylase KDM5A.
    Petronikolou N; Longbotham JE; Fujimori DG
    Biochemistry; 2020 Feb; 59(5):647-651. PubMed ID: 31985200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The KDM5A/RBP2 histone demethylase represses NOTCH signaling to sustain neuroendocrine differentiation and promote small cell lung cancer tumorigenesis.
    Oser MG; Sabet AH; Gao W; Chakraborty AA; Schinzel AC; Jennings RB; Fonseca R; Bonal DM; Booker MA; Flaifel A; Novak JS; Christensen CL; Zhang H; Herbert ZT; Tolstorukov MY; Buss EJ; Wong KK; Bronson RT; Nguyen QD; Signoretti S; Kaelin WG
    Genes Dev; 2019 Dec; 33(23-24):1718-1738. PubMed ID: 31727771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of ryuvidine as a KDM5A inhibitor.
    Mitsui E; Yoshida S; Shinoda Y; Matsumori Y; Tsujii H; Tsuchida M; Wada S; Hasegawa M; Ito A; Mino K; Onuki T; Yoshida M; Sasaki R; Mizukami T
    Sci Rep; 2019 Jul; 9(1):9952. PubMed ID: 31289306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human papillomavirus type 16 E7 oncoprotein-induced upregulation of lysine-specific demethylase 5A promotes cervical cancer progression by regulating the microRNA-424-5p/suppressor of zeste 12 pathway.
    Liu J; Zhao H; Zhang Q; Shi Z; Zhang Y; Zhao L; Ren Y; Ou R; Xu Y
    Exp Cell Res; 2020 Nov; 396(1):112277. PubMed ID: 32918895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased mitochondrial function downstream from KDM5A histone demethylase rescues differentiation in pRB-deficient cells.
    Váraljai R; Islam AB; Beshiri ML; Rehman J; Lopez-Bigas N; Benevolenskaya EV
    Genes Dev; 2015 Sep; 29(17):1817-34. PubMed ID: 26314709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of novel lysine demethylase 5-selective inhibitors by inhibitor-based fragment merging strategy.
    Miyake Y; Itoh Y; Hatanaka A; Suzuma Y; Suzuki M; Kodama H; Arai Y; Suzuki T
    Bioorg Med Chem; 2019 Mar; 27(6):1119-1129. PubMed ID: 30745098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insights into the Action of Inhibitor Enantiomers against Histone Lysine Demethylase 5A.
    Horton JR; Liu X; Wu L; Zhang K; Shanks J; Zhang X; Rai G; Mott BT; Jansen DJ; Kales SC; Henderson MJ; Pohida K; Fang Y; Hu X; Jadhav A; Maloney DJ; Hall MD; Simeonov A; Fu H; Vertino PM; Yan Q; Cheng X
    J Med Chem; 2018 Apr; 61(7):3193-3208. PubMed ID: 29537847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of ortho-hydroxy anilide as a novel scaffold for lysine demethylase 5 inhibitors.
    Jaikhan P; Buranrat B; Itoh Y; Chotitumnavee J; Kurohara T; Suzuki T
    Bioorg Med Chem Lett; 2019 May; 29(10):1173-1176. PubMed ID: 30928196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone demethylase KDM5A inhibits glioma cells migration and invasion by down regulating ZEB1.
    Dai B; Huang H; Guan F; Zhu G; Xiao Z; Mao B; Su H; Hu Z
    Biomed Pharmacother; 2018 Mar; 99():72-80. PubMed ID: 29324315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physical and functional interactions between the histone H3K4 demethylase KDM5A and the nucleosome remodeling and deacetylase (NuRD) complex.
    Nishibuchi G; Shibata Y; Hayakawa T; Hayakawa N; Ohtani Y; Sinmyozu K; Tagami H; Nakayama J
    J Biol Chem; 2014 Oct; 289(42):28956-70. PubMed ID: 25190814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.